This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Laura A. Petersen, MD, MPH; Jennifer Daley, MD

JAMA. 1996;275(23):1811-1812.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

General internists continue to find themselves in demand as health care systems focus on longitudinal care of chronic diseases and outpatient preventive services. New information about preventive health will affect practice. Previous studies on the primary prevention of coronary heart disease have shown that lowering cholesterol reduces the incidence of myocardial infarction (MI), but that mortality from noncardiovascular causes might be increased by treatment. In a randomized controlled trial, 6595 Scottish men aged 45 to 64 years with a mean (±SD) plasma cholesterol level of 7.0±0.6 mmol/L (272±23 mg/dL) were assigned to receive high-dose pravastatin sodium or placebo. During the average follow-up period of almost 5 years, the treated patients had a relative risk reduction for nonfatal MI or death from coronary heart disease of 31%. No excess deaths from noncardiovascular causes occurred in the treatment group.¹ A meta-analysis using pooled data from 4 double-blind atherosclerosis regression trials comparing . . . [Full Text PDF of this Article]

Author Affiliations
Brockton/West Roxbury Veterans Affairs Medical Center, West Roxbury, Mass, and Brigham and Women's Hospital and Harvard Medical School, Boston, Mass; Brockton/West Roxbury Veterans Affairs Medical Center, West Roxbury, Mass, and Beth Israel Hospital and Harvard Medical School, Boston, Mass

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?